The Diabetic Foot as a Proxy for Cardiovascular Events and Mortality Review

Current Atherosclerosis Reports

Volumn 19, Issue 11, 2017, Pages

  Dietrich, Isa ^a,b   Braga, Gustavo Arruda ^b   de Melo, Fernanda Gomes ^b   da Costa Silva Silva, Ana Carolina Calmon ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Organization Oswaldo Cruz German Hospital   (Brazil)

Author keywords

Cardiovascular events; Cardiovascular mortality; Diabetes; Diabetic foot syndrome; Foot ulcer; Microvascular disease; Neuropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

AMPUTATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC INFLAMMATION; CONGESTIVE HEART FAILURE; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LIFE EXPECTANCY; MALIGNANT NEOPLASM; METABOLIC SYNDROME X; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; WOUND HEALING IMPAIRMENT; WOUND INFECTION; COMPLICATION; DIABETIC ANGIOPATHY; DISEASE EXACERBATION; MORTALITY;

AMPUTATION; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; DIABETIC FOOT; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; HUMANS; RISK FACTORS;

EID: 85030626865     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-017-0680-z     Document Type: Review

References (36)

1. Global report on diabetes. World Health Organization. 2016. Available at: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1.
2. Mantovani AM, Fregonesi CE, Palma MR, Ribeiro FE, Fernandes RA, Christofaro DG. Relationship between amputation and risk factors in individuals with diabetes mellitus: a study with Brazilian patients. Diabetes Metab Syndr. 2017;11(1):47–50.
3. Chammas NK, Hill RL, Edmonds ME. Increased mortality in diabetic foot ulcer patients: the significance of ulcer type. J Diabetes Res. 2016;2016:2879809.
4. Volmer-Thole M, Lobmann R. Neuropathy and diabetic foot syndrome. Int J Mol Sci. 2016;17(6):917.
5. Amin N, Doupis J. Diabetic foot disease: from the evaluation of the “foot at risk” to the novel diabetic ulcer treatment modalities. World J Diabetes. 2016;7(7):153–64.
6. Noor S, Khan RU, Ahmad J.Understanding Diabetic Foot Infection and its Management, In Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;11(2):149–156.
7. Boyko EJ, et al. Increased mortality associated with diabetic foot ulcer. Diabet Med. 1996;13:967–72.
8. Rani V, Deep G, Singh RK, Palle K. Yadav UC oxidative stress and metabolic disorders: pathogenesis and therapeutic strategies. Life Sci. 2016;148:183–93.
9. Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diabetes Rep. 2016;16(3):29. https://doi.org/10.1007/s11892-016-0727-5.
10. Gómez-Marcos MÁ, Recio-Rodríguez JI, Patino-Alonso MC, et al. Evolution of target organ damage and haemodynamic parameters over 4 years in patients with increased insulin resistance: the LOD-DIABETES prospective observational study. BMJ Open. 2016;6(6):e010400. https://doi.org/10.1136/bmjopen-2015-010400.
11. Begun A, Morbach S, Rümenapf G, Icks A. Study of disease progression and relevant risk factors in diabetic foot patients using a multistate continuous-time markov chain model. PLoS One. 2016;11(1):e0147533. https://doi.org/10.1371/journal.pone.0147533.
12. Callaghan BC, Xia R, Banerjee M, de Rekeneire N, Harris TB, Health ABC Study, et al. Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. Diabetes Care. 2016;39(5):801–7.
13. Miric DJ, Kisic BM, Filipovic-Danic S, et al. Xanthine oxidase activity in type 2 diabetes mellitus patients with and without diabetic peripheral neuropathy. J Diabetes Res. 2016;2016:4370490, 7 pages.
14. Razzaghi R, et al. The effects of vitamin D supplementation on wound healing and metabolic status in patients with diabetic foot ulcer: a randomized, double-blind, placebo-controlled trial. J Diabetes Complicat. 2017;31(4):766–72. Published online in 2016
15. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629–38.
16. Lanting SM, Twigg SM, Johnson NA, Baker MK, Caterson ID, Chuter VH. Non-invasive lower limb small arterial measures co-segregate strongly with foot complications in people with diabetes. J Diabetes Complicat. 2017;31(3):589–93.
17. Juster-Switlyk K, Smith AG. Updates in diabetic peripheral neuropathy. F1000 Research. 2016;5:F1000 Faculty Rev-738. https://doi:10.12688/f1000research.7898.1.
18. Çakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH. Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med. 2016;33:1466–76.
19. Jeffcoate WJ, et al. Medial arterial calcification in diabetes and its relationship to neuropathy. Diabetologia. 2009;52:2478–88.
20. • Jhamb S, Vangaveti VN, Malabu UH. Genetic and molecular basis of diabetic foot ulcers: clinical review. J Tissue Viability. 2016;25(4):229–36. Discusses possible molecular targets linking diabetic foot and cardiovascular events.
21. Wang Z, Li L, Du R, Yan J, Liu N, Yuan W, et al. CML/RAGE signal induces calcification cascade in diabetes. Diabetol Metab Syndr. 2016;8:83.
22. Kay AM, Simpson CL, Stewart JA Jr. The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J Diabetes Res. 2016; https://doi.org/10.1155/2016/6809703.
23. •• Roustit M, Loader J, Deusenbery C, Baltzis D, Veves A. Endothelial dysfunction asa link between cardiovascular risk factors and peripheral neuropathy in diabetes. J Clin Endocrinol Metab. 2016;101:3401–8. Discusses common molecular pathways correlating distal peripheral neuropathy and endothelial dysfunction.
24. Kuehl M, Stevens MJ. Cardiovascular autonomic neuropathies as complications of diabetes mellitus. Nat Rev Endocrinol. 2012;28:405–16.
25. Scognamiglio R, Avogaro A, Casara D, Crepaldi C, Marin M, Palisi M, et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1998;31:404–12.
26. O'Sullivan JJ, Conroy RM, MacDonald K, McKenna TJ, Maurer BJ. Silent ischaemia in diabetic men with autonomic neuropathy. Br Heart J. 1991;66:313–5.
27. Yun JS, Cha SA, Lim TS, Lee EY, Song KH, Ahn YB, et al. Cardiovascular autonomic dysfunction predicts diabetic foot ulcers in patients with type 2 diabetes without diabetic polyneuropathy. Medicine (Baltimore). 2016;95:12.
28. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132–40.
29. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation. 2004;110(16):2342–8.
30. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352(20):2049–60.
31. Ogawa Y, Goto T, Tamasawa N, Matsui J, Tando Y, Sugimoto K, et al. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy. Diabetes Res Clin Pract. 2008;79(2):357–61.
32. Zhao J, Deng W, Zhang Y, Zheng Y, Zhou L, Boey J, et al. Association between serum cystatin C and diabetic foot ulceration in patients with type 2 diabetes: a cross-sectional study. J Diabetes Res. 2016; https://doi.org/10.1155/2016/8029340.
33. • Baltzis D, Roustit M, Grammatikopoulou MG, Katsaboukas D, Athanasiou V, Iakovou I, et al. Diabetic peripheral neuropathy as a predictor of asymptomatic myocardial ischemia in type 2 diabetes mellitus: a cross-sectional study. Adv Ther. 2016;33(10):1840–7. Correlates the presence of any peripheral stenosis and number of stenosed arteries with cardiac events.
34. Mohammedi K, Woodward M, Hirakawa Y, et al. Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study. Cardiovasc Diabetol. Mohammedi et al. Cardiovasc Diabetol. 2016;15:129.
35. McFarlane SI, Sowers JR. Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab. 2003;88(2):516–23. https://doi.org/10.1210/jc.2002-021443.
36. Dòria M, Rosado V, Pacheco LR, Hernández M, Betriu À, Valls J, et al. Prevalence of diabetic foot disease in patients with diabetes mellitus under renal replacement therapy in Lleida, Spain. Biomed Res Int. 2016;2016:7217586, 8 pages. https://doi.org/10.1155/2016/7217586.